# Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

> **NCT00353496** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 264 (actual)

## Conditions studied

- Endocrine Tumors

## Interventions

- **DRUG:** lanreotide (Autogel formulation)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00353496
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00353496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00353496, "Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00353496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*